- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | The privileged status of orphan medicines in Germany | ||
| Fr | Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks | ||
| Fr | Merck's net income for Q1 2024 increases by 69% to $4.76bn | ||
| Fr | Multiply Labs and GenScript partner on cell isolation automation | ||
| Fr | Regeneron and Mammoth team up to develop gene editing therapies | ||
| Fr | AstraZeneca posts $2.18bn profit after tax in Q1 2024 | ||
| Do | Sanders takes aim at US drug prices of Novo's Ozempic and Wegovy | ||
| Do | Cidara buys back rights to flu therapy from J&J for $85m | ||
| Do | Inflation Reduction Act to have knock on effect on R&D, say biotech experts | ||
| Do | Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture | ||
| Do | Merck plans €300m investment at new German research centre | ||
| Do | Mundipharma to acquire rezafungin assets from Cidara Therapeutics | ||
| Do | Life science SMEs "heading out of the funding winter" | ||
| Do | Biogen reports net income of $393.4m in Q1 2024 | ||
| Do | US FDA approves Utility Therapeutics' Pivya tablets for UTIs | ||
| Mi | Novartis bags paediatric FDA label expansion for Lutathera | ||
| Mi | GSK, Lundbeck, ROVI: Three Journeys of Unified Pharma Events Management | ||
| Mi | EC approves Astellas' Xtandi for high-risk prostate cancer treatment | ||
| Mi | Incyte signs deal to acquire Escient Pharmaceuticals | ||
| Mi | Pfizer and BioNTech commence legal action against Moderna in UK court | ||
| Mi | Novartis reports 25% increase in net income in Q1 2024 | ||
| Mi | Social prescribing: friend or foe for pharma? | ||
| Di | Hepion shelves Phase II NASH trial amid shallow cash resources | ||
| Di | Investors advocate for early biotech partnerships for later deal success | ||
| Di | Smaller regulators grasp innovation through international collaboration |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
